Shots:
Halozyme Therapeutics, via its subsidiary Halozyme Hypercon, has entered a global exclusive collaboration & license agreement with Vertex to utilize its Hypercon technology across up to three drug targets
As per the deal, Halozyme will receive $15M upfront, with additional milestone payments & royalties tied to products developed using the technology
Hypercon is a…
